Cite
HARVARD Citation
Chari, A. et al. (2021). Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study. British journal of haematology. pp. 869-878. [Online].